Date: 2014-03-03
Type of information: Nomination
Compound: chief medical officer, chief operating officer
Company: Amicus Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 3, 2014, Amicus Therapeutics announced the appointment of Jay A. Barth as chief medical officer. Dr. Barth brings to Amicus more than 15 years of experience in drug development, clinical research and medical affairs. He will be responsible for all clinical development activities as well as regulatory affairs. The company also announced the promotion of Bradley L. Campbell from chief business officer to chief operating officer, effective December 2013. Both Dr. Barth and Mr. Campbell report to John F. Crowley, Chairman and Chief Executive Officer of Amicus.
- Prior joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics, Inc. from 2009 to 2014. He most recently served as PTC\'s Senior Vice President, Clinical Development. In this role he led the clinical team and oversaw all global clinical development programs, focusing on rare diseases including Duchenne Muscular Dystrophy and Cystic Fibrosis. He also worked with PTC\'s regulatory affairs team to develop U.S. and European regulatory strategy, communicate with regulatory agencies, and prepare marketing applications for submission. Previously Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc. Dr. Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School of Medicine. He is a member of the American Gastroenterological Association, the American College of Gastroenterology, and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. He is also the author of numerous publications in the fields of medicine and clinical research.
- Mr. Campbell has over a decade of experience in the rare and orphan disease field at both Amicus and Genzyme. He joined Amicus in 2006 and has assumed positions of increasing responsibility, most recently serving as Chief Business Officer. In his new role, Mr. Campbell will remain the head of several departments including Business Development, Program Management, Commercial Planning, Patient and Professional Advocacy, and Technical Operations, with increased responsibility in overseeing preclinical research and development. Mr. Campbell received his B.A. in Public Policy from Duke University and his M.B.A. from Harvard Business School.
Financial terms:
Latest news:
Is general: Yes
